- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06934226
Studie k posouzení účinnosti a bezpečnosti JNJ-77242113 ve srovnání s placebem a ustekinumabem u účastníků se středně těžkou až těžkou plakovou psoriázou (ICONIC-ASCEND)
Multicentrická, randomizovaná, dvojitě slepá, placebem ovládaná a ustekinumab aktivní komparátor kontrolovaná studie pro vyhodnocení účinnosti a bezpečnosti JNJ-77242113 pro léčbu účastníků s mírnou až závažnou plaketovou psoriázou kontrolovanou studii.
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Barrio Gral Paz Cba Capital, Argentina, X5000
- Consultora Integral de Salud SRL
-
Buenos Aires, Argentina, B1643CRO
- Instituto Medico De Alta Complejidad (IMAC)
-
Buenos Aires, Argentina, C1417EYG
- Mindout Research
-
Buenos Aires, Argentina, C1425
- Instituto de Neumonologia y Dermatologia
-
CABA, Argentina, C1061AAS
- CIPREC
-
CABA, Argentina, C1199ABB
- Hospital Italiano de Buenos Aires
-
CABA, Argentina, C1055AAO
- Buenos Aires Skin
-
CABA, Argentina, C1056ABH
- Investigaciones Medicas IMOBA SRL
-
CABA, Argentina, C1128
- Mautalen Salud e Investigacion
-
Caba, Argentina, C1122AAF
- Halitus Instituto Medico S.A. - Dermatologia y Estetica
-
Rosario, Argentina, S2000DBS
- Instituto De Especialidades De La Salud SRL
-
San Fernando, Argentina, B1646
- MR Medicina Reumatologica
-
San Miguel de Tucumán, Argentina, T4000
- Instituto de Investigaciones Medicas Tucuman
-
-
-
-
-
Clayton, Austrálie, 3168
- Monash Medical Centre
-
Coorparoo, Austrálie, 4151
- Cornerstone Dermatology
-
Greenslopes, Austrálie, 4120
- Veracity Clinical Research
-
Kogarah, Austrálie, 2217
- Premier Specialists
-
Melbourne, Austrálie, 3004
- The Alfred Hospital
-
Melbourne, Austrálie, 3050
- Royal Melbourne Hospital
-
Mitcham, Austrálie, 3132
- ISHI dermatology
-
Westmead, Austrálie, 2145
- Westmead Hospital
-
-
-
-
-
Brussels, Belgie, 1090
- UZ Brussel
-
Ghent, Belgie, 9000
- Ghent University Hospital
-
Ghent, Belgie, 9000
- AZ St. Lucas
-
Leuven, Belgie, 3000
- Universitair Ziekenhuis Leuven
-
Liège, Belgie, 4000
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
Maldegem, Belgie, 9990
- Dermatologie Maldegem
-
-
-
-
-
Aalborg, Dánsko, 9100
- Aalborg Sygehus Syd
-
Aarhus, Dánsko, 8200
- Aarhus University Hospital
-
Hellerup, Dánsko, 2900
- Gentofte Hospital
-
København NV, Dánsko, 2400
- Bispebjerg Hospital
-
Odense, Dánsko, 5000
- Odense University Hospital
-
Roskilde, Dánsko, 4000
- Sjællands University hospital
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1E 1V4
- Skincare Studio Inc Dermatology Clinical Trials
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S7K8
- CCA Medical Research Corporation
-
Barrie, Ontario, Kanada, L4M 7G1
- SimcoDerm Medical and Surgical Dermatology Centre
-
Hamilton, Ontario, Kanada, L8N 1Y2
- Dermatrials Research
-
London, Ontario, Kanada, N6A 5R9
- Lovegrove Dermatology
-
Markham, Ontario, Kanada, L3P 1X3
- Lynderm Research Inc.
-
Waterloo, Ontario, Kanada, N2J 1C4
- Alliance Clinical Trials
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 2V1
- Innovaderm Research Inc.
-
Québec, Quebec, Kanada, G1W 4R4
- The Centre de recherche Saint-Louis
-
-
-
-
-
Budapest, Maďarsko, 1036
- Obudai Egeszsegugyi Centrum Kft
-
Budapest, Maďarsko, 1152
- Uno Medical Trials Ltd.
-
Debrecen, Maďarsko, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Debrecen, Maďarsko, 4031
- Derma-B Kft
-
Gyula, Maďarsko, 5700
- Synexus Magyarorszag Kft
-
Gyöngyös, Maďarsko, 3200
- Gyongyosi Bugat Pal Korhaz
-
Hódmezővásárhely, Maďarsko, 6800
- Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
-
Kaposvár, Maďarsko, 7400
- Somogy Varmegyei Kaposi Mor Oktato Korhaz
-
Kecskemét, Maďarsko, 6000
- Bacs-kiskun Megyei Korhaz
-
Szolnok, Maďarsko, 5000
- Allergo-Derm Bakos Kft.
-
Veszprém, Maďarsko, 8200
- Medmare Egeszsegugyi Es Szolgaltato Bt.
-
-
-
-
-
Augsburg, Německo, 86179
- Klinikum Augsburg
-
Bad Bentheim, Německo, 48455
- Fachklinik Bad Bentheim
-
Berlin, Německo, 10789
- ISA - Interdisciplinary Study Association GmbH
-
Bonn, Německo, 53127
- Universitatsklinikum Bonn
-
Bramsche, Německo, 49565
- Studienzentrum an der Hase GbR
-
Darmstadt, Německo, 64283
- Rosenpark Research GmbH
-
Dresden, Německo, 01307
- Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
-
Friedrichshafen, Německo, 88045
- Derma-Study-Center Friedrichshafen GmbH
-
Kiel, Německo, 24105
- Universitaetsklinikum Schleswig Holstein Campus Kiel
-
Langenau, Německo, 89129
- Studienzentrum Dr Schwarz Germany
-
Mahlow, Německo, 15831
- Dermatologie Mahlow
-
Mainz, Německo, 55128
- Gemeinschaftspraxis Dres. Quist
-
Münster, Německo, 48149
- Universitaetsklinikum Muenster
-
Witten, Německo, 58453
- Hautarztpraxis
-
-
-
-
-
Bialystok, Polsko, 15 375
- Specderm Poznanska sp j
-
Bialystok, Polsko, 15-351
- Osteo-Medic s.c A. Racewicz, J Supronik
-
Elblag, Polsko, 82 300
- Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
-
Katowice, Polsko, 40 568
- Care Clinic Sp z o o
-
Krakow, Polsko, 30 002
- Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
-
Lodz, Polsko, 90-265
- Dermed Centrum Medyczne Sp z o o
-
Olsztyn, Polsko, 10-117
- Etyka Osrodek Badan Klinicznych
-
Poznan, Polsko, 60 529
- SOLUMED Centrum Medyczne
-
Skierniewice, Polsko, 96 100
- Velocity Nova Sp z o o
-
Warsaw, Polsko, 02 661
- Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
-
Warsaw, Polsko, 02 953
- Klinika Ambroziak Dermatologia
-
Wroclaw, Polsko, 52 416
- Centrum Medyczne Oporow
-
Wroclaw, Polsko, 51 685
- WroMedica I Bielicka A Strzalkowska s c
-
-
-
-
-
Guimarães, Portugalsko, 4835 044
- Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
-
Leiria, Portugalsko, 2410 197
- Unidade Local De Saude Da Regiao De Leiria Epe
-
Lisbon, Portugalsko, 1169 050
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, Portugalsko, 1998 018
- Hosp. Cuf Descobertas
-
Porto, Portugalsko, 4099 001
- Ulssa Hosp. Santo Antonio
-
-
-
-
-
Feldkirch, Rakousko, 6800
- LKH Feldkirch
-
Linz, Rakousko, 4020
- Kepler Universitatsklinikum GmbH
-
Sankt Pölten, Rakousko, 3100
- Universtitatsklinikum St Poelten
-
Vienna, Rakousko, 1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
-
-
-
Dudley, Spojené království, DY1 2HQ
- Dudley Group NHS Foundation Trust
-
Harrow, Spojené království, HA1 3UJ
- London North West University Healthcare NHS Trust
-
Kings Lynn, Spojené království, PE30 4ET
- The Queen Elizabeth Hospital NHS Foundation Trust
-
London, Spojené království, SE1 9RT
- Guys and St Thomas NHS Foundation Trust
-
Reading, Spojené království, RG1 5AN
- Royal Berkshire Hospital
-
Salford, Spojené království, M6 8HD
- Salford Royal Hospital
-
Southampton, Spojené království, So166yd
- University Hospital Southampton
-
Wakefield, Spojené království, WF1 4DG
- Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35244
- Cahaba Research Inc
-
-
California
-
Encinitas, California, Spojené státy, 92024
- California Dermatology & Clinical Research Institute
-
Encino, California, Spojené státy, 91436
- T Joseph Raoof Md Inc
-
Fountain Valley, California, Spojené státy, 92708
- First OC Dermatology
-
Oceanside, California, Spojené státy, 92056
- Dermatologist Medical Group of North County, Inc.
-
Rocklin, California, Spojené státy, 95765
- NorCal Clinical Research
-
Sacramento, California, Spojené státy, 95815
- Integrative Skin Science and Research
-
San Diego, California, Spojené státy, 92103
- MedDerm Associates
-
Santa Ana, California, Spojené státy, 92701
- Southern California Dermatology
-
Sylmar, California, Spojené státy, 91342
- Olive View-UCLA Education & Research Institute
-
-
Connecticut
-
Farmington, Connecticut, Spojené státy, 06030
- University of Conn Health Center
-
-
Florida
-
Miami, Florida, Spojené státy, 33155
- Bioclinical Research Alliance Inc.
-
Miami, Florida, Spojené státy, 33126
- Driven Research LLC
-
Ocala, Florida, Spojené státy, 34470
- Renstar Medical Research
-
Tampa, Florida, Spojené státy, 33613
- Forcare Clinical Research Inc
-
-
Georgia
-
Alpharetta, Georgia, Spojené státy, 30022
- Hamilton Research LLC
-
-
Illinois
-
Skokie, Illinois, Spojené státy, 60076
- Northshore Medical Group
-
-
Indiana
-
Plainfield, Indiana, Spojené státy, 46168
- Indiana Clinical Trial Center
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa
-
-
Kentucky
-
Bowling Green, Kentucky, Spojené státy, 42104
- Equity Medical
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02111
- Tufts Medical Center
-
Brighton, Massachusetts, Spojené státy, 02135
- Metro Boston Clinical Partners
-
-
Michigan
-
Caledonia, Michigan, Spojené státy, 49316
- The Derm Institute of West Michigan
-
Detroit, Michigan, Spojené státy, 48202
- Henry Ford Hospital
-
Fort Gratiot, Michigan, Spojené státy, 48059
- Hamzavi Dermatology
-
Troy, Michigan, Spojené státy, 48084
- Somerset Skin Centre
-
-
Minnesota
-
New Brighton, Minnesota, Spojené státy, 55112
- Minnesota Clinical Study Center
-
-
Missouri
-
Kirksville, Missouri, Spojené státy, 63501
- Cleaver Dermatology
-
Saint Joseph, Missouri, Spojené státy, 64506
- MediSearch Clinical Trials
-
-
New York
-
New York, New York, Spojené státy, 10075
- Sadick Research Group
-
New York, New York, Spojené státy, 10028
- Mount Sinai Doctors Dermatology
-
-
North Carolina
-
Wilmington, North Carolina, Spojené státy, 28405
- Wilmington Dermatology Center
-
-
Ohio
-
Boardman, Ohio, Spojené státy, 44512
- Optima Research
-
Mayfield Heights, Ohio, Spojené státy, 44124
- Apex Dermatology Mayfield Heights
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Spojené státy, 97201
- Oregon Medical Research Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19114
- Clinical Research Philadelphia
-
Pittsburgh, Pennsylvania, Spojené státy, 15213
- UPMC Department of Dermatology
-
-
South Dakota
-
Rapid City, South Dakota, Spojené státy, 57702
- Health Concepts
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37211
- Advanced Research Experts PLLC
-
-
Texas
-
Arlington, Texas, Spojené státy, 76011
- Arlington Research Center, Inc.
-
Dallas, Texas, Spojené státy, 75231
- Modern Research Associates PLLC
-
Houston, Texas, Spojené státy, 77004
- Center for Clinical Studies 1
-
San Antonio, Texas, Spojené státy, 78218
- Texas Dermatology and Laser Specialists
-
San Antonio, Texas, Spojené státy, 78213
- Progressive Clinical Research
-
Webster, Texas, Spojené státy, 77598
- Center for Clinical Studies
-
-
Utah
-
West Valley City, Utah, Spojené státy, 84120
- Kalo Clinical Research
-
-
Washington
-
Mill Creek, Washington, Spojené státy, 98012
- Frontier Derm Partners CRO, LLC
-
-
-
-
-
Alicante, Španělsko, 03010
- Hosp. Gral. Univ. Dr. Balmis
-
Barakaldo, Španělsko, 48902
- Hosp. Univ. de Cruces
-
Barcelona, Španělsko, 08036
- Hosp. Clinic de Barcelona
-
Granada, Španělsko, 18016
- Hosp. Univ. San Cecilio
-
Madrid, Španělsko, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Španělsko, 28006
- Hosp. Univ. de La Princesa
-
Madrid, Španělsko, 28002
- Grupo Dermatologico Y Estetico Pedro Jaen
-
Manises, Španělsko, 46940
- Hosp. de Manises
-
Santiago Compostela, Španělsko, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, Španělsko, 41009
- Hosp. Virgen Macarena
-
Seville, Španělsko, 41014
- Hosp. Ntra. Sra. de Valme
-
Valencia, Španělsko, 46026
- Hosp. Univ. I Politecni La Fe
-
Villajoyosa, Španělsko, 03570
- Hosp. de La Marina Baixa
-
Zaragoza, Španělsko, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
Zaragoza, Španělsko, 50009
- Hosp. Univ. Miguel Servet
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) >=12 at screening and baseline
- Total investigator global assessment (IGA) >=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria:
- Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
- Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm 1: JNJ 77242113
Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. |
|
Komparátor placeba: Arm 2: Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. Matching placebo will be administered orally. |
|
Aktivní komparátor: Arm 3: Ustekinumab
Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28. |
JNJ-77242113 will be administered orally. Matching placebo will be administered orally. Ustekinumab will be administered subcutaneously.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Časové okno: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Časové okno: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Časové okno: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Časové okno: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Časové okno: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Časové okno: Week 28
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Časové okno: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Časové okno: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Časové okno: Week 16
|
PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Časové okno: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Časové okno: Up to Week 108
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important. |
Up to Week 108
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Časové okno: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Časové okno: Baseline up to Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Časové okno: Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Časové okno: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Časové okno: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Časové okno: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Časové okno: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Časové okno: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Časové okno: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Časové okno: Baseline up to Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Časové okno: Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Časové okno: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Časové okno: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Časové okno: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Časové okno: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 77242113PSO3006
- 77242113PSO3006 (Jiný identifikátor: Janssen Research & Development, LLC)
- 2024-515706-77-00 (Identifikátor registru: EUCT number)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .